Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [1]
- Blocking/Neutralizing [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF1162 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal BAFFR/TNFRSF13C Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human BAFF R in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross-reactivity with recombinant mouse BAFF R and less than 2% cross-reactivity with recombinant human (rh) 4-1BB, rhCD27, rhCD30, rhCD40, rhDR3, rhDR6, rhEDAR, rhFas, rhGITR, rhHVEM, rhNGF R, rhOPG, rhRANK, rhTNF RI, and rhTNF RII is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells.
Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand.
Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells.
BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Requirement for BAFF and APRIL during B cell development in GALT.
BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells.
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.
Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma.
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.
Saulep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM, Tam C, Mackay F
Leukemia 2016 Jan;30(1):163-72
Leukemia 2016 Jan;30(1):163-72
Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand.
Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J
Nature communications 2014 Jun 9;5:4092
Nature communications 2014 Jun 9;5:4092
Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.
Luster TA, Mukherjee I, Carrell JA, Cho YH, Gill J, Kelly L, Garcia A, Ward C, Oh L, Ullrich SJ, Migone TS, Humphreys R
PloS one 2012;7(10):e47361
PloS one 2012;7(10):e47361
APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells.
Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, Sabour-Alaoui S, Pediaditakis I, Dessirier V, Gravanis A, Stathopoulos EN, Tsapis A, Castanas E
Journal of immunology (Baltimore, Md. : 1950) 2012 Nov 15;189(10):4748-58
Journal of immunology (Baltimore, Md. : 1950) 2012 Nov 15;189(10):4748-58
BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Ohmatsu H, Sugaya M, Miyagaki T, Suga H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S
The British journal of dermatology 2012 Aug;167(2):359-67
The British journal of dermatology 2012 Aug;167(2):359-67
Requirement for BAFF and APRIL during B cell development in GALT.
Yeramilli VA, Knight KL
Journal of immunology (Baltimore, Md. : 1950) 2010 May 15;184(10):5527-36
Journal of immunology (Baltimore, Md. : 1950) 2010 May 15;184(10):5527-36
BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.
Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, Lapree G, Tsapis A, Richard Y
Blood 2008 Mar 1;111(5):2744-54
Blood 2008 Mar 1;111(5):2744-54
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 1;13(19):5903-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 1;13(19):5903-9
IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells.
Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE
Journal of immunology (Baltimore, Md. : 1950) 2007 Mar 1;178(5):2872-82
Journal of immunology (Baltimore, Md. : 1950) 2007 Mar 1;178(5):2872-82
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.
Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM
Blood 2006 Apr 1;107(7):2882-8
Blood 2006 Apr 1;107(7):2882-8
Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma.
Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD
Journal of immunology (Baltimore, Md. : 1950) 2005 Mar 1;174(5):3015-23
Journal of immunology (Baltimore, Md. : 1950) 2005 Mar 1;174(5):3015-23
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.
Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, Krishnan SR, Planta MA, Turney JF, Justement JS, Kottilil S, Dybul M, Mican JM, Kovacs C, Chun TW, Birse CE, Fauci AS
The Journal of experimental medicine 2004 Oct 4;200(7):587-99
The Journal of experimental medicine 2004 Oct 4;200(7):587-99
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- BAFF R/TNFRSF13C in Human Spleen. BAFF R/TNFRSF13C in Human Spleen.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Detection of BAFF R/TNFRSF13C in PBMCs by Flow Cytometry. Detection of BAFF R/TNFRSF13C in PBMCs by Flow Cytometry.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- BAFF R/TNFRSF13C Inhibition of BAFF/BLys/ TNFSF13B-dependent Cell Proliferation and Neutralization by Human BAFF R/TNFRSF13C Antibody. Recombinant Human BAFF R/TNFRSF13C Fc Chimera (Catalog # 1162-BR) inhibits Recombinant Human BAFF/BLyS/TNFSF13B (Catalog # 2149-BF) induced proliferation in mouse B cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human BAFF/BLyS/TNFSF13B (5 ng/mL) activity elicited by Recombinant Human BAFF R/TNFRSF13C Fc Chimera (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human BAFF R/TNFRSF13C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1162). The ND50 is typically 3-15 µg/mL.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- BAFF R/TNFRSF13C Inhibition of BAFF/BLys/ TNFSF13B-dependent Cell Proliferation and Neutralization by Human BAFF R/TNFRSF13C Antibody.
